anti-PD1/PDL1 inhibitors
3 abstracts
Abstract
Timing of immunotherapy in stage IV non-small cell lung cancer.Org: Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Yufu, Japan, Penn State Health Milton S. Hershey Medical Center,
Abstract
Are severe immune-related adverse events more likely in patients with pre-existing autoimmune disease?Org: Dept of Medicine, UCLA Geffen School of Medicine, UCLA-Olive View Health System, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, David Geffen School of Medicine at UCLA,
Abstract
Cost-effectiveness of novel systemic therapies for advanced breast cancer: Global representativeness and influence of funding.Org: Instituto do Câncer do Estado de São Paulo (ICESP), University of São Paulo/ICESP, São Paulo, SP, Brazil, Sao Paulo State Cancer Institute (ICESP), São Paulo, Brazil,